Skip to main content

Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="23" name="CC Event Nav"]
A mobile computerized tomographic lung screening program detected a high number of incidental concurrent disease findings in a rural underserved high-risk population of heavy smokers. Read More ›

Analysis of the National Cancer Database indicates that a lower proportion of black patients with locally advanced, stage III, non–small-cell lung cancer (NSCLC) receive concurrent chemotherapy plus radiotherapy compared with white patients. Read More ›

Significant racial disparities exist among lung cancer survivors in receipt of surveillance scans, guidance about follow-up care, and smoking cessation. Read More ›

Atezolizumab in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC) extends disease-free survival compared with best supportive care after receiving adjuvant chemotherapy. Read More ›

Findings from KEYNOTE-598 detected no difference in health-related quality of life or time to true deterioration in lung cancer symptoms comparing treatment with pembrolizumab + ipilimumab versus pembrolizumab + placebo in patients with previously untreated metastatic non–small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score ≥50%. Read More ›

Patients with pretreated KRAS p.G12C–mutated non–small-cell lung cancer (NSCLC) treated with sotorasib improved or maintained global health status/quality of life, physical functioning, and the severity of key lung cancer–related symptoms. Read More ›

Modeling of the ADAURA trial data showed that 3 years of adjuvant osimertinib was more cost-effective than placebo in EGFR-mutated non–small-cell lung cancer (NSCLC). Read More ›

The cost burden of adjunctive osimertinib therapy is higher than the observed clinical benefit for patients with resected EGFR-positive non–small-cell lung cancer (NSCLC). Read More ›

The ACCURE intervention using a combination of real-time electronic health record monitoring, nurse navigation, and race-based feedback significantly improved delivery of timely lung cancer surgery and markedly reduced racial disparities for patients with early-stage lung cancer. Read More ›

Sotorasib, an oral KRAS inhibitor, was effective across specified subgroups of patients with KRAS G12C–mutated non–small-cell lung cancer (NSCLC). Read More ›

Page 10 of 27